首页 > 最新文献

Laryngo-rhino-otologie最新文献

英文 中文
[Rare entity of a supraglottic laryngeal tumour in a lung transplant patient]. [肺移植患者罕见的声门上型喉肿瘤]。
IF 0.9 4区 医学 Q3 OTORHINOLARYNGOLOGY Pub Date : 2024-09-30 DOI: 10.1055/a-2410-1973
Martin Sorge, Alexandra Wald, Marie Erika Eva Liebetrau, Andreas Dietz, Susanne Wiegand, Matthaeus Stoehr
{"title":"[Rare entity of a supraglottic laryngeal tumour in a lung transplant patient].","authors":"Martin Sorge, Alexandra Wald, Marie Erika Eva Liebetrau, Andreas Dietz, Susanne Wiegand, Matthaeus Stoehr","doi":"10.1055/a-2410-1973","DOIUrl":"https://doi.org/10.1055/a-2410-1973","url":null,"abstract":"","PeriodicalId":17965,"journal":{"name":"Laryngo-rhino-otologie","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142349304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Nasal hemorrhage - risk factors and management in 707 outpatient and inpatient patients]. [鼻出血--707 名门诊和住院病人的风险因素和处理方法]。
IF 0.9 4区 医学 Q3 OTORHINOLARYNGOLOGY Pub Date : 2024-09-09 DOI: 10.1055/a-2406-5519
Nikita Breyer, Benjamin Mayer, Jörg Lindemann, Thomas Karl Hoffmann, Janina Hahn

Epistaxis is one of the most common emergencies in otorhinolaryngology. The spectrum ranges from mild, self-limiting cases to life-threatening hemorrhages. Depending on the severity and course of the condition, management can be either outpatient or involve inpatient monitoring, possibly with surgical treatment.A retrospective systematic evaluation was conducted on all outpatient and inpatient patient data diagnosed with epistaxis from January to December 2021. Epistaxis associated with tumors, trauma, and postoperative epistaxis were excluded.A total of 707 patients were included. Seasonally, the highest number of patients presented in January. Outpatient management was possible for 80.8% of the cases, while 19.2% required inpatient admission. Among the inpatients, 15.4% required surgical intervention. Within the entire study cohort, 61.1% of the patients were male. Among the inpatients who underwent surgical treatment, the proportion of male patients was even higher (81.0%). The majority (73.1%) of the inpatients were on at least one anticoagulant medication. Advanced age (p=0.044) and the presence of posterior epistaxis (p<0.001) were significantly associated with the need for inpatient treatment. No children required inpatient care.Epistaxis is a common condition in otorhinolaryngology, predominantly affecting older male patients and those on anticoagulant therapy in severe cases within the studied cohort. Surgical intervention under general anesthesia was infrequently necessary for the treatment of epistaxis in the overall study population (3%).

鼻衄是耳鼻喉科最常见的急症之一。其范围从轻微的自限性病例到危及生命的大出血不等。根据病情的严重程度和病程,治疗方式可以是门诊治疗,也可以是住院观察,可能还需要手术治疗。共纳入 707 名患者。从季节上看,1 月份的患者人数最多。80.8%的病例可以在门诊治疗,19.2%的病例需要住院治疗。在住院患者中,15.4%需要手术治疗。在整个研究队列中,61.1% 的患者为男性。在接受手术治疗的住院患者中,男性患者的比例更高(81.0%)。大多数住院患者(73.1%)至少服用一种抗凝药物。高龄(p=0.044)和后鼻衄(p
{"title":"[Nasal hemorrhage - risk factors and management in 707 outpatient and inpatient patients].","authors":"Nikita Breyer, Benjamin Mayer, Jörg Lindemann, Thomas Karl Hoffmann, Janina Hahn","doi":"10.1055/a-2406-5519","DOIUrl":"https://doi.org/10.1055/a-2406-5519","url":null,"abstract":"<p><p>Epistaxis is one of the most common emergencies in otorhinolaryngology. The spectrum ranges from mild, self-limiting cases to life-threatening hemorrhages. Depending on the severity and course of the condition, management can be either outpatient or involve inpatient monitoring, possibly with surgical treatment.A retrospective systematic evaluation was conducted on all outpatient and inpatient patient data diagnosed with epistaxis from January to December 2021. Epistaxis associated with tumors, trauma, and postoperative epistaxis were excluded.A total of 707 patients were included. Seasonally, the highest number of patients presented in January. Outpatient management was possible for 80.8% of the cases, while 19.2% required inpatient admission. Among the inpatients, 15.4% required surgical intervention. Within the entire study cohort, 61.1% of the patients were male. Among the inpatients who underwent surgical treatment, the proportion of male patients was even higher (81.0%). The majority (73.1%) of the inpatients were on at least one anticoagulant medication. Advanced age (p=0.044) and the presence of posterior epistaxis (p<0.001) were significantly associated with the need for inpatient treatment. No children required inpatient care.Epistaxis is a common condition in otorhinolaryngology, predominantly affecting older male patients and those on anticoagulant therapy in severe cases within the studied cohort. Surgical intervention under general anesthesia was infrequently necessary for the treatment of epistaxis in the overall study population (3%).</p>","PeriodicalId":17965,"journal":{"name":"Laryngo-rhino-otologie","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142290327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Needs analysis for self-help training in the context of cochlear implant rehabilitation]. [人工耳蜗康复自助培训需求分析]。
IF 0.9 4区 医学 Q3 OTORHINOLARYNGOLOGY Pub Date : 2024-09-03 DOI: 10.1055/a-2389-5457
Sophie Geßner, Sylvia Meuret, Michael Fuchs, Kathleen Tretbar

Objective: Despite cochlear implantation, CI users experience difficulties in challenging listening situations. In German-speaking countries, there are no interventions to promote specific coping strategies for such situations. The present study examines persistent everyday limitations and the relevance of potential intervention content in order to develop a self-help program for CI rehabilitation.

Material and methods: 56 CI users from three German CI centers were recruited and completed an online survey on demographic data, hearing biography, hearing handicap and potentially relevant intervention content. The intervention content presented included the following categories: Medical Aspects, Communication Improvement Aspects, Psychosocial Aspects, Technical Aspects, Specific Aspects.

Results: The hearing handicap was moderate to severe in this sample. The content categories presented for the design of a self-help program were all rated as "important". The duration of CI provision correlated significantly negatively with the assessment of the relevance of psychosocial aspects. Further significant correlations were found between the severity of the hearing handicap and the rating of the relevance of aspects for improving communication, psychosocial and technical aspects.

Conclusion: A self-help program that takes into account the contents examined could provide promising support for the CI rehabilitation process and will be developed and evaluated subsequently.

目的:尽管植入了人工耳蜗,但 CI 使用者在具有挑战性的听力环境中仍会遇到困难。在德语国家,还没有针对这种情况的干预措施来促进特定的应对策略。材料与方法:本研究从德国三家人工耳蜗中心招募了 56 名人工耳蜗用户,并完成了一项关于人口统计学数据、听力简历、听力障碍和潜在相关干预内容的在线调查。提出的干预内容包括以下类别:结果:结果:该样本的听力障碍程度为中度至重度。设计自助计划的内容类别均被评为 "重要"。提供 CI 的时间长短与社会心理方面的相关性评估呈显著负相关。听力障碍的严重程度与改善沟通、社会心理和技术方面的相关性评价之间也存在明显的相关性:考虑到所研究内容的自助计划可为 CI 康复过程提供有前景的支持,并将在随后进行开发和评估。
{"title":"[Needs analysis for self-help training in the context of cochlear implant rehabilitation].","authors":"Sophie Geßner, Sylvia Meuret, Michael Fuchs, Kathleen Tretbar","doi":"10.1055/a-2389-5457","DOIUrl":"https://doi.org/10.1055/a-2389-5457","url":null,"abstract":"<p><strong>Objective: </strong>Despite cochlear implantation, CI users experience difficulties in challenging listening situations. In German-speaking countries, there are no interventions to promote specific coping strategies for such situations. The present study examines persistent everyday limitations and the relevance of potential intervention content in order to develop a self-help program for CI rehabilitation.</p><p><strong>Material and methods: </strong>56 CI users from three German CI centers were recruited and completed an online survey on demographic data, hearing biography, hearing handicap and potentially relevant intervention content. The intervention content presented included the following categories: Medical Aspects, Communication Improvement Aspects, Psychosocial Aspects, Technical Aspects, Specific Aspects.</p><p><strong>Results: </strong>The hearing handicap was moderate to severe in this sample. The content categories presented for the design of a self-help program were all rated as \"important\". The duration of CI provision correlated significantly negatively with the assessment of the relevance of psychosocial aspects. Further significant correlations were found between the severity of the hearing handicap and the rating of the relevance of aspects for improving communication, psychosocial and technical aspects.</p><p><strong>Conclusion: </strong>A self-help program that takes into account the contents examined could provide promising support for the CI rehabilitation process and will be developed and evaluated subsequently.</p>","PeriodicalId":17965,"journal":{"name":"Laryngo-rhino-otologie","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142126106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Correction: The multicenter registry "oropharyngeal cancer" of the German ENT Study Center - First Results]. [更正:德国耳鼻喉研究中心 "口咽癌 "多中心登记--初步结果]。
IF 0.9 4区 医学 Q3 OTORHINOLARYNGOLOGY Pub Date : 2024-09-02 DOI: 10.1055/a-2404-2934
Dirk Beutner, Nicolas Bevis, Carlotta Derad, Thomas Asendorf, Ralf Tostmann, Heinrich Iro, Jens Peter Klußmann, Orlando Guntinas-Lichius
{"title":"[Correction: The multicenter registry \"oropharyngeal cancer\" of the German ENT Study Center - First Results].","authors":"Dirk Beutner, Nicolas Bevis, Carlotta Derad, Thomas Asendorf, Ralf Tostmann, Heinrich Iro, Jens Peter Klußmann, Orlando Guntinas-Lichius","doi":"10.1055/a-2404-2934","DOIUrl":"https://doi.org/10.1055/a-2404-2934","url":null,"abstract":"","PeriodicalId":17965,"journal":{"name":"Laryngo-rhino-otologie","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142120170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Dizziness and hearing loss after Valsalva maneuver]. [瓦尔萨尔瓦手法后出现头晕和听力损失]。
IF 0.9 4区 医学 Q3 OTORHINOLARYNGOLOGY Pub Date : 2024-09-01 Epub Date: 2024-06-24 DOI: 10.1055/a-2318-6877
Andrea Tröger, Timo Gottfried, Philipp Zelger, Gerlig Widmann, Joachim Schmutzhard
{"title":"[Dizziness and hearing loss after Valsalva maneuver].","authors":"Andrea Tröger, Timo Gottfried, Philipp Zelger, Gerlig Widmann, Joachim Schmutzhard","doi":"10.1055/a-2318-6877","DOIUrl":"10.1055/a-2318-6877","url":null,"abstract":"","PeriodicalId":17965,"journal":{"name":"Laryngo-rhino-otologie","volume":" ","pages":"663-664"},"PeriodicalIF":0.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11368484/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141446477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fall chronischer Tinnitus. 慢性耳鸣病例
IF 0.9 4区 医学 Q3 OTORHINOLARYNGOLOGY Pub Date : 2024-09-01 Epub Date: 2024-09-02 DOI: 10.1055/a-2316-3105
{"title":"Fall chronischer Tinnitus.","authors":"","doi":"10.1055/a-2316-3105","DOIUrl":"10.1055/a-2316-3105","url":null,"abstract":"","PeriodicalId":17965,"journal":{"name":"Laryngo-rhino-otologie","volume":"103 9","pages":"683"},"PeriodicalIF":0.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142120176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Systemic therapies for advanced thyroid cancer - an update]. [晚期甲状腺癌的系统疗法--最新进展]。
IF 0.9 4区 医学 Q3 OTORHINOLARYNGOLOGY Pub Date : 2024-09-01 Epub Date: 2024-02-12 DOI: 10.1055/a-2249-2239
Tim Brandenburg, Yara Maria Machlah, Dagmar Führer-Sakel

Based on phase III clinical studies, four multi-kinase inhibitors (MKI) are approved for the treatment of progressive radioiodine-refractory differentiated thyroid carcinoma (rrDTC) and medullary thyroid carcinoma (MTC) in Germany. Only recently, based on the randomized trial COSMIC-311, Cabozantinib has been approved as a second-line treatment option in advanced rrDTC. As first in-label selective RET-Inhibitor, Selpercatinib showed promising efficacy in advanced MTC (first line) with RET mutations and rrDTC (second line) with RET fusions along with fewer side effects. Changes and new approaches for the treatment of ATC have been summarised in the current ATA guidelines.

基于III期临床研究,德国批准了四种多激酶抑制剂(MKI)用于治疗进展期放射性碘难治性分化型甲状腺癌(rrDTC)和甲状腺髓样癌(MTC)。直到最近,基于随机试验 COSMIC-311,Cabozantinib 才被批准作为晚期 RrDTC 的二线治疗方案。作为首个标签内选择性RET抑制剂,赛乐替尼(Selpercatinib)在RET突变的晚期MTC(一线)和RET融合的rrDTC(二线)中显示出良好的疗效,且副作用较小。目前的 ATA 指南总结了 ATC 治疗的变化和新方法。
{"title":"[Systemic therapies for advanced thyroid cancer - an update].","authors":"Tim Brandenburg, Yara Maria Machlah, Dagmar Führer-Sakel","doi":"10.1055/a-2249-2239","DOIUrl":"10.1055/a-2249-2239","url":null,"abstract":"<p><p>Based on phase III clinical studies, four multi-kinase inhibitors (MKI) are approved for the treatment of progressive radioiodine-refractory differentiated thyroid carcinoma (rrDTC) and medullary thyroid carcinoma (MTC) in Germany. Only recently, based on the randomized trial COSMIC-311, Cabozantinib has been approved as a second-line treatment option in advanced rrDTC. As first in-label selective RET-Inhibitor, Selpercatinib showed promising efficacy in advanced MTC (first line) with RET mutations and rrDTC (second line) with RET fusions along with fewer side effects. Changes and new approaches for the treatment of ATC have been summarised in the current ATA guidelines.</p>","PeriodicalId":17965,"journal":{"name":"Laryngo-rhino-otologie","volume":" ","pages":"637-642"},"PeriodicalIF":0.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139723192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Results of a survey on the current management of chronic rhinosinusitis with nasal polyps in Germany]. [德国慢性鼻炎伴鼻息肉治疗现状调查结果]。
IF 0.9 4区 医学 Q3 OTORHINOLARYNGOLOGY Pub Date : 2024-09-01 Epub Date: 2024-04-02 DOI: 10.1055/a-2246-2793
Eric Deuss, Sven Becker, Moritz Meyer, Timon Hussain, Jonas Eckrich, Stephan Lang, Ludger Klimek, Benjamin Ernst

Introduction: With a prevalence of 0.55% to 4%, chronic rhinosinusitis with nasal polyps (CRSwNP) is a relevant part of the daily work of German otolaryngologists. The aim of the questionnaire-based data collection was to assess the current treatment status of CRSwNP in Germany.

Material and methods: For this purpose, 24 questions within an anonymized online questionnaire were sent to all German ENT departments.

Results: Of 160 contacted ENT departments, 50 participated in the survey (31.3%). Among these, 76% performed more than 100 sinus surgeries annually and 38% treated more than 50 patients with biologics. Saline irrigations (80%) and intranasal glucocorticoids (GCS, 96%) were the most common conservative therapies. Systemic GCSs (52%) and intranasal GCS irrigation (20%) were less common. 80% of departments used biologics in the therapy of CRSwNP with an overall preference for dupilumab (70%). For therapy of aspirin intolerance, biologics (52%) were preferred to aspirin desensitization (26%). Prior to treatment with biologics clinical workup included the nasal polyp score (90%), the SNOT-22 questionnaire (84%), surrogate markers of type 2 inflammation (60%-72%), and computer tomography (50%). Final treatment success was assessed after 24 weeks (50%).

Conclusion: Mostly, the responding departments followed German and European recommendations for diagnosis and therapy of CRSwNP. Therapy with biologics is widely used. The value of preoperative systemic GCS and the frequent performance of CT before initiation of therapy with a biologic should be debated in regard to its currently widespread use.

简介慢性鼻炎伴鼻息肉(CRSwNP)的发病率为 0.55% 至 4%,是德国耳鼻喉科医生日常工作的重要组成部分。此次问卷调查的目的是评估德国目前CRSwNP的治疗状况:为此,我们向德国所有耳鼻喉科部门发送了一份匿名在线问卷,其中包含 24 个问题:结果:在联系的 160 家耳鼻喉科中,有 50 家参与了调查(31.3%)。其中,76%的耳鼻喉科每年进行的鼻窦手术超过 100 例,38%的耳鼻喉科使用生物制剂治疗的患者超过 50 例。盐水冲洗(80%)和鼻内糖皮质激素(GCS,96%)是最常见的保守疗法。系统性糖皮质激素(52%)和鼻内糖皮质激素冲洗(20%)则不太常见。80% 的科室在治疗 CRSwNP 时使用生物制剂,总体上倾向于使用 dupilumab(70%)。在治疗阿司匹林不耐受时,生物制剂(52%)比阿司匹林脱敏(26%)更受青睐。使用生物制剂治疗前的临床检查包括鼻息肉评分(90%)、SNOT-22 问卷(84%)、2 型炎症的代用指标(60%-72%)和计算机断层扫描(50%)。最终治疗成功率在 24 周后进行评估(50%):大多数受访部门都遵循了德国和欧洲关于 CRSwNP 诊断和治疗的建议。生物制剂治疗得到广泛应用。鉴于生物制剂目前的广泛应用,术前全身 GCS 的价值以及在开始使用生物制剂治疗前频繁进行 CT 检查的做法值得商榷。
{"title":"[Results of a survey on the current management of chronic rhinosinusitis with nasal polyps in Germany].","authors":"Eric Deuss, Sven Becker, Moritz Meyer, Timon Hussain, Jonas Eckrich, Stephan Lang, Ludger Klimek, Benjamin Ernst","doi":"10.1055/a-2246-2793","DOIUrl":"10.1055/a-2246-2793","url":null,"abstract":"<p><strong>Introduction: </strong>With a prevalence of 0.55% to 4%, chronic rhinosinusitis with nasal polyps (CRSwNP) is a relevant part of the daily work of German otolaryngologists. The aim of the questionnaire-based data collection was to assess the current treatment status of CRSwNP in Germany.</p><p><strong>Material and methods: </strong>For this purpose, 24 questions within an anonymized online questionnaire were sent to all German ENT departments.</p><p><strong>Results: </strong>Of 160 contacted ENT departments, 50 participated in the survey (31.3%). Among these, 76% performed more than 100 sinus surgeries annually and 38% treated more than 50 patients with biologics. Saline irrigations (80%) and intranasal glucocorticoids (GCS, 96%) were the most common conservative therapies. Systemic GCSs (52%) and intranasal GCS irrigation (20%) were less common. 80% of departments used biologics in the therapy of CRSwNP with an overall preference for dupilumab (70%). For therapy of aspirin intolerance, biologics (52%) were preferred to aspirin desensitization (26%). Prior to treatment with biologics clinical workup included the nasal polyp score (90%), the SNOT-22 questionnaire (84%), surrogate markers of type 2 inflammation (60%-72%), and computer tomography (50%). Final treatment success was assessed after 24 weeks (50%).</p><p><strong>Conclusion: </strong>Mostly, the responding departments followed German and European recommendations for diagnosis and therapy of CRSwNP. Therapy with biologics is widely used. The value of preoperative systemic GCS and the frequent performance of CT before initiation of therapy with a biologic should be debated in regard to its currently widespread use.</p>","PeriodicalId":17965,"journal":{"name":"Laryngo-rhino-otologie","volume":" ","pages":"646-654"},"PeriodicalIF":0.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140860543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Use of tobacco cigarettes, e-cigarettes, and shishas among children and adolescents: Results of the "Präventionsradar" from 2016 to 2023]. [儿童和青少年使用烟草卷烟、电子烟和香烟的情况:2016年至2023年'预防雷达'的结果]。
IF 0.9 4区 医学 Q3 OTORHINOLARYNGOLOGY Pub Date : 2024-09-01 Epub Date: 2024-02-26 DOI: 10.1055/a-2249-3796
Reiner Hanewinkel, Julia Hansen

Aim: To measure trends in the use of various smoking products among children and adolescents from 2016 to 2023.

Method: The data is based on seven waves of the "Präventionsradar", a school-based epidemiological study in grades 5 to 10. The primary endpoints of the study were the lifetime and monthly prevalence of the use of tobacco cigarettes, e-cigarettes, shisha and the use of at least two of these smoking products (combined use). Prevalence estimates are based on logistic regression models.

Results: The analysis was based on 94,127 questionnaires. The sex ratio was balanced (49% female), mean age was 13 years (SD=1.8). In 2022/2023, the lifetime prevalence of smoking tobacco cigarettes was 18.8% (95% CI 18.1-19.5), of e-cigarettes 23.5% (95% CI 22.8-24.3), of shisha 14.0% (95% CI 13.4-14.7) and combined use 19.0% (95% CI 18.3-19.7). The monthly prevalence of smoking tobacco cigarettes was 5.9% (95% CI 5.5-6.4), of e-cigarettes 7.0% (95% CI 6.5-7.4), of shisha 3.2% (95% CI 2.8-3.5) and combined use 4.8% (95% CI 4.4-5.2). The following trends in lifetime prevalence have emerged since 2016: tobacco cigarettes (-3.0 percentage points), e-cigarettes (+1.8 percentage points), shisha (-9.2 percentage points), combined use (-2.7 percentage points). In the years of the COVID-19 pandemic, youth smoking decreased and rose again post-COVID with the exception of shisha.

Discussion: The use of smoking products in adolescence occurs frequently. Over the observational period, a trend reversal towards e-cigarettes as the most popular product among children and young people is most likely. In addition, the combined use of several smoking products has become a common pattern of consumption. Consistent preventive measures are required in order to achieve the goal of a smoke-free society in 2040.

目的:测量2016年至2023年儿童和青少年使用各种吸烟产品的趋势:数据基于七次 "Präventionsradar "调查,这是一项针对五至十年级学生的学校流行病学调查。研究的主要终点是烟草香烟、电子烟、水烟的终生使用率和每月使用率,以及至少使用其中两种吸烟产品(合并使用)的情况。流行率估计基于逻辑回归模型:分析基于 94 127 份问卷。性别比例均衡(49% 为女性),平均年龄为 13 岁(SD=1.8)。2022/2023 年,终生吸烟率为 18.8% (95% CI 18.1-19.5),电子烟为 23.5% (95% CI 22.8-24.3),水烟为 14.0% (95% CI 13.4-14.7),综合吸烟率为 19.0% (95% CI 18.3-19.7)。每月吸烟率为 5.9% (95% CI 5.5-6.4),电子烟为 7.0% (95% CI 6.5-7.4),水烟为 3.2% (95% CI 2.8-3.5),合并吸烟率为 4.8% (95% CI 4.4-5.2)。自 2016 年以来,终生吸烟率出现了以下趋势:烟草卷烟(-3.0 个百分点)、电子烟(+1.8 个百分点)、水烟(-9.2 个百分点)、混合使用(-2.7 个百分点)。在 COVID-19 大流行的几年中,青少年吸烟率有所下降,COVID 后又有所上升,但水烟除外:讨论:青少年经常使用烟草制品。在观察期内,最有可能出现的趋势是电子烟成为最受儿童和青少年欢迎的产品。此外,联合使用多种吸烟产品已成为一种常见的消费模式。为了在 2040 年实现无烟社会的目标,需要采取持续的预防措施。
{"title":"[Use of tobacco cigarettes, e-cigarettes, and shishas among children and adolescents: Results of the \"Präventionsradar\" from 2016 to 2023].","authors":"Reiner Hanewinkel, Julia Hansen","doi":"10.1055/a-2249-3796","DOIUrl":"10.1055/a-2249-3796","url":null,"abstract":"<p><strong>Aim: </strong>To measure trends in the use of various smoking products among children and adolescents from 2016 to 2023.</p><p><strong>Method: </strong>The data is based on seven waves of the \"Präventionsradar\", a school-based epidemiological study in grades 5 to 10. The primary endpoints of the study were the lifetime and monthly prevalence of the use of tobacco cigarettes, e-cigarettes, shisha and the use of at least two of these smoking products (combined use). Prevalence estimates are based on logistic regression models.</p><p><strong>Results: </strong>The analysis was based on 94,127 questionnaires. The sex ratio was balanced (49% female), mean age was 13 years (SD=1.8). In 2022/2023, the lifetime prevalence of smoking tobacco cigarettes was 18.8% (95% CI 18.1-19.5), of e-cigarettes 23.5% (95% CI 22.8-24.3), of shisha 14.0% (95% CI 13.4-14.7) and combined use 19.0% (95% CI 18.3-19.7). The monthly prevalence of smoking tobacco cigarettes was 5.9% (95% CI 5.5-6.4), of e-cigarettes 7.0% (95% CI 6.5-7.4), of shisha 3.2% (95% CI 2.8-3.5) and combined use 4.8% (95% CI 4.4-5.2). The following trends in lifetime prevalence have emerged since 2016: tobacco cigarettes (-3.0 percentage points), e-cigarettes (+1.8 percentage points), shisha (-9.2 percentage points), combined use (-2.7 percentage points). In the years of the COVID-19 pandemic, youth smoking decreased and rose again post-COVID with the exception of shisha.</p><p><strong>Discussion: </strong>The use of smoking products in adolescence occurs frequently. Over the observational period, a trend reversal towards e-cigarettes as the most popular product among children and young people is most likely. In addition, the combined use of several smoking products has become a common pattern of consumption. Consistent preventive measures are required in order to achieve the goal of a smoke-free society in 2040.</p>","PeriodicalId":17965,"journal":{"name":"Laryngo-rhino-otologie","volume":" ","pages":"655-662"},"PeriodicalIF":0.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139972516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Direktes Feedback während der Insertion der Elektrode des Cochlea-Implantats. 插入人工耳蜗电极时的直接反馈。
IF 0.9 4区 医学 Q3 OTORHINOLARYNGOLOGY Pub Date : 2024-09-01 Epub Date: 2024-09-02 DOI: 10.1055/a-2331-4536
{"title":"Direktes Feedback während der Insertion der Elektrode des Cochlea-Implantats.","authors":"","doi":"10.1055/a-2331-4536","DOIUrl":"https://doi.org/10.1055/a-2331-4536","url":null,"abstract":"","PeriodicalId":17965,"journal":{"name":"Laryngo-rhino-otologie","volume":"103 9","pages":"629-630"},"PeriodicalIF":0.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142120174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Laryngo-rhino-otologie
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1